药源性肥胖精神病人替换齐拉西酮治疗的临床研究  

Clinical study on Ziprasidone replacement therapy in psychiatric patients with drug-induced obesity

作　　者：苏建宁 陈年梅 王魁元 方锋峰 胡文芳 SU Jianning;CHEN Nianmei;WANG Kuiyuan(Third People's Hospital of Ganzhou,Ganzhou,341000,China)

机构地区：[1]江西省赣州市第三人民医院

出　　处：《江西医药》2019年第9期1007-1009,共3页Jiangxi Medical Journal

基　　金：江西省赣州市指导性科技计划，编号GZ2016ZSF230

摘　　要：目的探讨药源性肥胖精神病人替换齐拉西酮治疗后对体质量、糖脂代谢、治疗疗效、依从性的影响。方法选取药源性肥胖精神病患者120例,对照组60例维持原药物治疗,研究组60例替换齐拉西酮治疗,持续观察随访24周,测评替换前及替换后4、8、16、24周的体质量、血糖、血脂、治疗依从性、疗效及不良反应。结果替换后研究组的疗效及依从性与对照组比较无显著差异(P>0.05);研究组的血糖在8周后显著低于对照组(P<0.05);研究组的体质量、甘油三酯、胆固醇在16周后均显著低于对照组(P<0.05);研究组的不良反应例次高于对照组(P<0.05)。结论药源性肥胖病人替换齐拉西酮治疗后疗效相当,在控制体质量、改善糖脂代谢方面获益明显。Objective To explore the effects of ziprasidone replacement therapy on body mass, glycolipid metabolism, treatment efficacy and compliance in psychiatric patients with drug-induced obesity.Methods 120 cases of psychiatric outpatients or inpatients with drug-induced obesity from January 2017 to December 2017 were selected.60 cases in control group were given maintenance of the original drug, and 60 cases in study group were treated with ziprasidone replacement therapy.The patients were followed up for 24 weeks, and body mass, blood glucose, blood lipids, treatment compliance, efficacy and adverse reactions were measured before replacement and at4, 8, 16, and 24 weeks after replacement, and the above indexes were compared between-groups and within-groups before and after replacement.Results After treatment, there was no significant difference in the efficacy and treatment compliance between study group and control group (P>0.05).The body mass and blood glucose, triglyceride and cholesterol in study group were significantly lower than those in control group after 16 weeks (P<0.05).The adverse reactions in study group were higher than those in control group (P<0.05).Conclusion The efficacy of ziprasidone replacement therapy is equivalent in psychiatric patients with drug-induced obesity.Ziprasidone can effectively control body mass, improve abnormal glycolipid metabolism.

关 键 词：精神病 药源性肥胖 齐拉西酮 替换治疗 

分 类 号：R749.3[医药卫生—神经病学与精神病学]